Does the improvement in RFS after FLAG-IDA + GO lead to more severe toxicities in CBF AML?

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Gautam M. Borthakur, MD Anderson Cancer Center, Houston, US. We asked: Does the improvement in relapse-free survival after FLAG-IDA + gemtuzumab ozogamicin (GO) come at the cost of more severe toxicities in patients with core binding factor acute myeloid leukemia (CBF AML)?

Gautam Borthakur discusses the best regimens for the treatment of CBF AML, he explains FLAG-IDA based regimen gives a good patient outcome and he questions the associated toxicities that come from the addition of GO to the regimen. He then explains the FLAG-IDA + GO has proven efficacious such as better patient responses, including higher rates of relapse-free survival and MRD-negativity.